{"type":"trials","record":{"id":41423,"source_id":"clinicaltrials-gov","external_id":"NCT06961370","title":"A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)","brief_summary":"The main purpose of this study is to assess the ocular and systemic safety and tolerability of RO7669330 in participants with GA secondary to AMD in at least one eye in Part 1, or both eyes in Part 2, after multiple unilateral intravitreal (IVT) doses.","overall_status":"Terminated","phases":["PHASE1"],"study_type":"INTERVENTIONAL","sponsor":"Hoffmann-La Roche","enrollment":27,"countries":["United States"],"start_date":"2025-07-16","completion_date":"2026-03-03","last_update_date":"2026-08-10","source_url":"https://clinicaltrials.gov/study/NCT06961370","editorial_summary":"A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"55 Years","comparator":null,"organization":"Hoffmann-La Roche","interventions":["RO7669330","Syfovre™","Izervay™"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Number of Participants With Adverse Events (AEs) — Up to a maximum of 34 weeks","Number of Participants With Abnormalities Recorded in Standard Ophthalmological Assessments — Up to a maximum of 34 wee…","Part 1A and Part 2: Ocular and Systemic Concentration of RO7669330 — Up to a maximum of Week 24"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · TRIPLE","source_has_results":false},"controlled_terms":["Geographic Atrophy","Age-related Macular Degeneration","RO7669330","Syfovre™","Izervay™"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct06961370","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2025-07-16 to 2026-03-03","comparator":null,"confidence":"structured-source","population":"ALL · 55 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.809Z","intervention":["RO7669330","Syfovre™","Izervay™"],"participants":27,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · TRIPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE1","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Number of Participants With Adverse Events (AEs) — Up to a maximum of 34 weeks","Number of Participants With Abnormalities Recorded in Standard Ophthalmological Assessments — Up to a maximum of 34 wee…","Part 1A and Part 2: Ocular and Systemic Concentration of RO7669330 — Up to a maximum of Week 24"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41423","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}